E-cigarette Causing Cessation during Pregnancy?

Industry Insight by 2FIRSTS.ai
Sep.14.2023
E-cigarette Causing Cessation during Pregnancy?
A new study from the University at Buffalo suggests that using e-cigarettes before pregnancy may increase the likelihood of quitting smoking during pregnancy.

According to a recent study released by the University at Buffalo, using e-cigarettes prior to pregnancy increases the likelihood of smoking cessation during pregnancy, compared to using nicotine replacement therapy (NRT). Despite the widely recognized risks of smoking during pregnancy to both maternal and fetal health, only about half of pregnant women are able to quit smoking on their own.

 

In order to investigate the impact of e-cigarettes or nicotine replacement therapy on smoking cessation in the later stages of pregnancy, researchers compared the quit rates of these two groups. This observational study collected data from 1,329 pregnant women between 2016 and 2020 through the US Pregnancy Risk Assessment Monitoring System (PRAMS). It is one of the first studies in the United States to examine the use of e-cigarettes by pregnant women.

 

Dr. Xiaozhong Wen, an associate professor at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, has conducted multiple studies in the field of behavioral medicine on smoking cessation during pregnancy and postpartum period.

 

He expressed his views after the publication of his research.

 

The urgency of studying the use of e-cigarettes among pregnant women is undeniable, as e-cigarette consumption has become increasingly prevalent among young people, including pregnant women.

 

A study has revealed that among 1,329 respondents who had previously used e-cigarettes or nicotine replacement therapy, approximately half (50.8%) of e-cigarette users claimed to quit smoking in the later stages of pregnancy. On the other hand, only 19.4% of individuals who used some form of nicotine replacement therapy successfully quit smoking.

 

A sub-group analysis of the study revealed that individuals who started using e-cigarettes before pregnancy had a higher smoking cessation rate (53.1%), whereas those who began using e-cigarettes during pregnancy had a similar smoking cessation rate (20.6%) to users of nicotine replacement therapy (19.4%).

 

Although the specific reasons are currently unclear, Wen Xiaozhong believes that there may be several possible explanations.

 

He stated, "The use of e-cigarettes may potentially assist patients in retaining tobacco-related hand movements, psychological gratification, social interaction, and engagement with other smokers."

 

He further added that e-cigarettes generally do not cause side effects like nausea, vomiting, sleep problems, headaches, etc., as nicotine replacement therapy does.

 

While this study may suggest that individuals who want to quit smoking during pregnancy could consider using e-cigarettes, it emphasizes the need for cautious interpretation of the findings and further confirmation through future randomized controlled trials.

 

He stated, "We have found that the association between e-cigarette use and smoking cessation during pregnancy may not be a causal relationship, particularly due to the presence of numerous important confounding factors, such as smoking intensity."

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.